Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"phase 3 as penny stock again - has any other bio done that ?"
Lol John, you're prepared for the worst
It is hard to believe a biotech stock in phase 3 trail with SPA & Orphan Drug designations is worth only about the cash it holds...
THIS IS RIDICULOUS!
Thanks for the link Farmer
Thanks for the post junior
Hi guys, did anything happen to psoriasis hitting market?
I been gone a while, that's why asking in the board
If you watch CNBC, they show a list of stocks at the bottom of screen....
ADXS shows up every rarely, and this was the first time I saw ADXS and ADRO at the same time in that list....
Nothing meaningful, but exciting since it's an ultra rare occurrence
HOLY COW! CNBC runs a stock symbols lost at the bottom of screen.... and ADRO and ADXS showed up on the screen at the same time at 5:31pm Eastern Time (Cramer show ongoing - BUY BUY BUY)
Good post, thanks wellness. Does anyone know any expected timeline for ADXS-PSA Combo data with Merk?
That could be a catalyst as well... acceptable results with ADXS Mono, but extraordinary results with ADXS Keytruda Combo? And then Merk will take more interest?
Just that alone could give us a huge lift????
Thanks for the post, of Dew is buying more so am I!!!! Bought more today.
ADXS Short profits from IEX. I'm not sure if that's valid, saw info online and figured I'd share:
Shorts Have Realized a Year to Date Return of: 55.94%
Shorts Have Realized a One Month Return of 26.34%
Shorts Have Realized a 5 Day Return of: 2.94%
Nice post, thanks gbrown.
This makes me even more confident about ADXS. If PETX AT-014 approval goes off track worst case, we're still game on... not giving up!
A statement from PETX 10-Q:
"We intend to focus our oncology research and development efforts on other therapeutic candidates in our pipeline, including the Live Listeria Vector platform. "
One thing that's done right is "Interim" CEO... I am a proponent of deliver before you earn that CEO title...
Let's see what Lombardo's got.... or it would be even better if the ADXS BOD is searching for a strong CEO in parallel...
ADXS Volume cooling down... that I don't like...
Where's the buyers at... ADXS is dirt cheap...
Hi girlfriend,
Looks like our retirement island vacation is getting delayed a bit? Lol
I am so overbought in ADXS and so num to ADXS Free Falling... no feelings...
Someone needs to pinch me or something...
Thanks for the post. A good sanity check to ensure ADXS Management is aware
Can someone please contact ADXS IR and put a response on this board...
I am having no luck getting them :(
And the same could be said for Adage who sold 20%
"Short interest in ADXS won't ever go to 0. We just need to see it go under 7M,"
The fact that tutes selling out ADXS shares (Adage, Broadfin, etc.) should have meant more opportunity to short... But that is not the case...
Short interest decreasing while available shares in market increasing is not logical, another sign something could be brewing....
"somebody or multiple somebodies really wanted out of this stock over the last month+. The question is will it ever end?"
Broadfin is completely out (not just ADXS but other stocks also) and Adage has sold a significant amount....
I do have three dots to connect (which I mentioned in the past):
1. DOC gets kicked out from ADXS (proof: DOC got some shitty BOD position, indicating his leave was not his willful)
2. Every time ADXS crosses over $4 Adage does a small burst of sell to pull it back.... and Adage only started selling after DOC's leave...
3. Short position went down from 10 million to 8 million in a 15 day period...
A BIG-BOYS GAME IS BEING PLAYED HERE....
Lol @ approx. $90 million cash on hand and $157 million market cap....
This is Unreal...
Connect a few dots here....
1. DOC gets a boot from ADXS (he got some lousy BOD position now, which is proof that he didn't leave according to his will)
2. Adage sells out 30% of its ADXS position so far...
3. ADXS total short has decreased by 20% so far... (from 10 million shorts to 8 million shorts).....
All of this points to short term pain for long term good.....
I haven't been following closely recently... DOC's selling shares as well?
I have a feeling Adage won't let ADXS go past $5 as it keeps selling in $4s...
But nothing lasts for forever.... This is more of a conviction that DOC and Adage were in together.....
Nahhh.. AT-014 is nothing in terms of revenue...
However, it is priceless for us longs as to proof that ADXS technology hit the market for real
PETX released news on ENTYCE, hitting market...
AT-014 next... both PETX and ADXS can use this bump
Damn Adage is letting out shares continuously... I been out for a week just looked
I'm pretty sure that PETX has 3 drugs approved and seeking re approval in the 3rd... excluding AT-014
Yes, good point.
A valid point terry, if I was running something personally, it would break my heart to sell a partnership where my profit share would be lost forever....
But at the same time, partnerships provide upfront cash and share of the same business risk....
Also, If I have a choice of partnership vs. dilution when stock is at yearly lows.... it would be silly to dilute
Possible cash other than dilution:
Amgen payments
Stendhal payments
Asian partnerships payments
PETX AT-014 approval payments and royalties
Additional partnerships (EU, other LM platforms, etc.)
Dilution should be the last option with so many other options at hand....
Also, ADXS Quarterly statements to SEC do state every time that they have enough cash to last until 2019
Meant to say June
PETX disclosed its AT-014 submission in its 2nd quarterly statement for month ending July 2017.
They submitted for approval in July.
"Our partner, Aratana, had three drugs listed. "
That's because Aratana has a total of three drugs approved to date. They messed up the third approval cuz they didn't have manufacturing capability, pending reapproval
So short term pain for long term benefit.... I hope
Here's one more dot to connect:
The fact that DOC got a BOD position at some other company means that he got kicked out of ADXS....
Had DOC gotten a position at big shot company or another CEO position, that would have leaned towards DOC leaving ADXS... but that's not the case
DOC leaves, shorties push price down harder, Adage and some other tutes pull out (Broadfin completely out)....
Hmmmm... how do we connect these dots?
Good point regarding end of quarter in 2 days...
Maybe that's why tutes including Adage selling out to balance overall profits and losses?
Hopefully more buying after end of quarter?
ADXS even higher at $4.69 after hours with relatively higher volume...
Also, tax cut news will boost all smallcap biotechs in general...
This is gonna fly the next few days hopefully